Royalty Pharma Plc Stock Price, News & Analysis

Royalty Pharma (RPRX) has completed the acquisition of its external manager, RP Management, LLC, with 99.9% shareholder approval. The internalization marks a significant shift from the company's previous external management model that had been in place since 1996. Under the former structure, Royalty Pharma paid quarterly fees of 6.5% of Portfolio Receipts and 0.25% of security investments value to RP Management.

The transaction integrates all RP Management employees into Royalty Pharma. Management team members (excluding CEO Pablo Legorreta) will receive about 50% of transaction equity, vesting through 2033. Legorreta's equity will vest over five years. The company will update its 2025 guidance to reflect this change in Q2 2025 results.

Royalty Pharma (NASDAQ: RPRX) has announced its participation in two major healthcare investor conferences in May 2025. The company will present at the BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET, and at the RBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET.

Both presentations will be available via webcast through Royalty Pharma's investor relations website and will remain archived for at least thirty days after the events.

Royalty Pharma (NASDAQ: RPRX) has received overwhelming shareholder approval (99.9% of votes) to acquire its external manager. The internalization transaction, valued at approximately $1.1 billion, will be paid primarily through 24.5 million shares of equity (vesting over 5-9 years), $100 million in cash, and assumption of $380 million in Manager debt.

The acquisition brings significant benefits including projected cash savings of over $100 million in 2026, growing to over $175 million by 2030, with cumulative savings exceeding $1.6 billion over ten years. The transaction will transform Royalty Pharma from an external management model to an integrated corporate structure, with all Manager employees becoming direct company employees.

Royalty Pharma (RPRX) reported strong Q1 2025 financial results with Portfolio Receipts growing 17% to $839 million and Royalty Receipts up 12% to $788 million. The company raised its full-year 2025 guidance, now expecting Portfolio Receipts between $2,975-$3,125 million. Key highlights include: repurchase of 23 million shares for $723 million, a 5% dividend increase, and $101 million in capital deployment. Strong performance was driven by the cystic fibrosis franchise, Trelegy, and Xtandi. The company is on track to acquire its external manager in Q2 2025, expecting to generate over $100 million in cash savings by 2026. The quarter saw positive clinical updates, including FDA and EC approvals for Tremfya in Crohn's disease and ulcerative colitis.

Ferring Pharmaceuticals has received FDA approval for a new drug product manufacturing facility in Parsippany, NJ, for ADSTILADRIN®, their intravesical non-replicating gene therapy. This milestone triggers a final $200 million payment from Royalty Pharma (RPRX).

The new 12,000-square-foot facility becomes the company's third manufacturing site for ADSTILADRIN, joining existing operations in Kuopio, Finland. The state-of-the-art facility features renewable energy solutions and specialized modern technology to ensure sustainable supply for anticipated global demand.

ADSTILADRIN is the first FDA-approved intravesical non-replicating gene therapy for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. Bladder cancer ranks as the sixth most diagnosed cancer in the United States, with most patients diagnosed with non-muscle invasive disease.

Royalty Pharma (Nasdaq: RPRX) has announced its quarterly dividend declaration for Q2 2025. The company's board of directors has approved a dividend payment of $0.22 per Class A ordinary share. The dividend is scheduled to be distributed on June 10, 2025, to shareholders who are recorded in the company's books at the close of business on May 16, 2025.

Royalty Pharma (Nasdaq: RPRX) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time on the same day.

Investors can access the conference call details and live webcast through the company's website at their Investors page. A replay of both the call and webcast will remain available on the website for a minimum of 30 days.

Royalty Pharma (RPRX) has appointed Dr. Vlad Coric to its Board of Directors, effective immediately. Dr. Coric, currently Chairman and CEO of Biohaven, brings over 20 years of drug discovery and clinical development experience from Yale School of Medicine and Bristol-Myers Squibb.

Under his leadership at Biohaven, Dr. Coric achieved significant milestones including:

• FDA approval and launch of Nurtec ODT for migraine treatment
• NDA filing for zavegepant, the first intranasal CGRP antagonist for migraine
• Led Biohaven's growth from founding through its $13 billion sale to Pfizer in May 2022

His expertise spans multiple therapeutic areas including neurology, psychiatry, immunology, virology, oncology and immuno-oncology. Dr. Coric completed his medical education at Wake Forest University and postdoctoral training at Yale School of Medicine.

Royalty Pharma (Nasdaq: RPRX) has announced plans to host an Investor Day on September 11, 2025, in New York City. The event will commence at 8:30 a.m. ET.

During the event, senior executives will present updates on the company's strategy for creating shareholder value by leveraging its distinctive business model and capabilities in the biopharma innovation funding market. The presentation will include interactive Q&A sessions.

Investors can access the live webcast through the 'Investors' section of Royalty Pharma's website, where it will remain archived for at least thirty days.